A recent study from the National Bureau of Economic Research finds that while effective for blood sugar management, GLP-1 medications show limited evidence of improving mental health, employment, or marriage in adults with diabetes over short to medium terms, raising questions about their wider social effects.
A new economic analysis from the National Bureau of Economic Research suggests that GLP-1 drugs, while clearly effective for diabetes care, may not translate into measurable gains in mental health, employment or marital status over the short to medium term.
The working paper, by Robert Kaestner of the University of Chicago Harris School of Public Policy and Cuiping Schiman, examined more than a decade of federal survey data from the Medical Expenditure Panel Survey. Looking at adults with diabetes from 2012 to 2023, the researchers tracked people before and after they began GLP-1 treatment rather than comparing users with non-users. On that basis, the paper found no meaningful change in self-rated health, mental health, work status or marriage after treatment began.
Kaestner and Schiman’s approach matters because it tries to separate the effect of the medicine from the characteristics of the people most likely to receive it. The paper found that some apparent differences between GLP-1 users and non-users disappeared once the analysis was restricted to changes within the same individuals. The authors said the survey measures were useful but limited, and that they may miss more subtle shifts such as confidence, relationship quality or day-to-day well-being.
The results do not challenge the well-established medical benefits of GLP-1 drugs. Clinical trials and other research have already shown that the medicines can improve blood sugar control, support weight loss and reduce cardiovascular risk. Instead, the paper addresses a narrower question that has become more important as prices remain high and coverage decisions are debated: whether the drugs deliver broader life changes beyond the clinic.
That debate is already shaping policy. According to the Centers for Medicare and Medicaid Services, a new Medicare GLP-1 Bridge demonstration began on 1 July and will run through 31 December 2027, allowing eligible Part D beneficiaries access to certain weight-loss GLP-1 medicines for a $50 monthly copay. For insurers, employers and public programmes, evidence of economic or social gains would strengthen the case for wider access. This paper did not find such gains in the outcomes it could measure.
The study’s authors and outside researchers also caution against overreading a null result. The paper is a working paper, not a peer-reviewed journal article, and it focused on adults with diabetes during a period when these drugs were used mainly for that condition rather than for obesity alone. A separate NBER paper by Rebecca Diamond, which looked at women using GLP-1s for weight loss, reported stronger effects on marriage or cohabitation and on employment among women who were not working at baseline. Another NBER analysis using Danish data found lower long-term sickness leave, but no meaningful effect on employment or income. Taken together, the studies suggest that the wider social effects of GLP-1s may depend heavily on who is taking them, why they are taking them and for how long.
For patients, the practical message is more restrained. The paper does not support stopping or changing treatment on its own, and it should not be taken to mean the medicines do not work. What it does suggest is that patients should not assume a GLP-1 drug will resolve depression, repair a relationship or transform a job situation. Those outcomes, if they change at all, may be too subtle for broad survey data to detect or may simply depend on factors outside the medication itself.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
